Grey Wolf was founded by leading scientists, drug developers and investors committed to translating the broad therapeutic potential of ERAP-driven antigen modulation into next generation therapies for patients with immunologically-driven diseases. Grey Wolf is a clinical-stage, UK- and Australia-based drug discovery and development company spearheading a new therapeutic strategy based on a first-of-its-kind approach to antigen modulation. The company’s innovative technology is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a central role in the antigen presentation pathway. The company is leveraging its leadership in the area of ERAP inhibition and antigen modulation to advance novel therapeutic approaches to address the source of immune dysfunction in oncology and autoimmunity.